基质金属蛋白酶基因多态性与冠心病的关系

Relationship between Polymorphisms of Matrix Metalloproteinase and Coronary Heart Disease

目的:探讨基质金属蛋白酶基因MMP-3、MMP-9和MMP-12启动子基因多态性与冠心病及其血浆水平的关系。方法:对经冠状动脉(冠脉)造影证实的急性心肌梗死患者59例(AMI组)、稳定性心绞痛患者58例(SAP组)和99例经冠脉造影证实无冠状病变的对照组进行了研究。ELISA法检测血浆MMPs的水平,多聚酶链反应-限制性内切酶片段长度多态性法(PCR-RFLP法)分析MMP-3、MMP-9、MMP-12启动子的3个部位基因型变异状况和等位基因分布频率。结果:AMI组和SAP组血浆MMP-9水平明显高于对照组(P<0.05)。各组基因型和等位基因频率分布差异无统计学意义(P>0.05)。未检出MMP-12启动子的-82A/G变异的基因型。不同基因型之间血浆MMPs的水平差异无统计学意义(P>0.05)。结论:MMP-3和MMP-9启动子区域两个位点的基因变异不影响其血浆水平的表达。未发现天津地区MMP-12的-82位A/G变异的基因多态现象,血浆MMP-9水平升高与冠心病发病有关。

Objective： To investigate the relationship between the plasma levels of matrix metalloproteinase （MMP）-3,9,12 and their promoter polymorphisms in patients with coronary heart disease. Methods： The study involved 59 patients with acute myocardial infarction （AMI）, 58 patients with stable angina pectoris （SAP） and 99 controls, all of which were confirmed by angiocardiography. Plasma levels of MMPs were measured by enzyme-linked immunosorbent assay （ELISA）. Promoter polymorphisms of MMP-3, 9 and 12 were analyzed by polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP）. Results： Plasma MMP-9 levels in patients with AMI and SAP were significantly higher than those of the controls （P 〈 0.05）. No significant difference was detected in the distribution of genotype and allele frequency among groups （P 〉 0.05）. There were also no significant differences in the plasma MMPs levels among the genotypes（P 〉 0.05）. Conclusion： The promoter gene variation had no influence on the plasma levels of MMPs. The substitution of -82 A/G in MMP-12 was not found in the study. The plasma MMP-9 level may effect the development of coronary heart disease.